News >

Treatment Options Expanding for Benign Hematologic Disorders

Brandon Scalea
Published: Tuesday, Apr 30, 2019

Nathan T. Connell, MD, MPH

Nathan T. Connell, MD, MPH

The addition of eltrombopag (Promacta) has expanded the treatment armamentarium for patients with benign hematologic disorders such as severe aplastic anemia and immune thrombocytopenia (ITP), said Nathan T. Connell, MD, MPH.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication